Literature DB >> 33917535

Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.

Shuja Sheikh1, Usman Alvi1, Betty Soliven1, Kourosh Rezania1.   

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the postsynaptic membrane resulting in damage to postsynaptic membrane, decreased number of AChRs or blocking of the receptors by autoantibodies. A number of drugs such as immune checkpoint inhibitors, penicillamine, tyrosine kinase inhibitors and interferons may induce de novo MG by altering the immune homeostasis mechanisms which prevent emergence of autoimmune diseases such as MG. Other drugs, especially certain antibiotics, antiarrhythmics, anesthetics and neuromuscular blockers, have deleterious effects on neuromuscular transmission, resulting in increased weakness in MG or MG-like symptoms in patients who do not have MG, with the latter usually being under medical circumstances such as kidney failure. This review summarizes the drugs which can cause de novo MG, MG exacerbation or MG-like symptoms in nonmyasthenic patients.

Entities:  

Keywords:  aminoglycoside; anesthesia; antibiotics; checkpoint inhibitor; corticosteroid; fluoroquinolone; macrolide; myasthenia gravis; sugammadex; tyrosine kinase inhibitor

Year:  2021        PMID: 33917535     DOI: 10.3390/jcm10071537

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  13 in total

1.  Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Authors:  Mirjana Zdraljevic; Stojan Peric; Marta Jeremic; Dragana Lavrnic; Ivana Basta; Ljiljana Hajdukovic; Dejana R Jovanovic; Ivana Berisavac
Journal:  Neurol Sci       Date:  2022-09-09       Impact factor: 3.830

2.  Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey.

Authors:  Milada Mahic; Ali M Bozorg; Jonathan J DeCourcy; Keisha J Golden; Gregor A Gibson; Christian F Taylor; Angela Ting; Tyler J Story; Anna Scowcroft
Journal:  Neurol Ther       Date:  2022-07-20

Review 3.  The relationship between myasthenia gravis and COVID-19: a systematic review.

Authors:  Dodik Tugasworo; Aditya Kurnianto; Yovita Andhitara; Rahmi Ardhini; Jethro Budiman
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-07-07

4.  Unmasking of Myasthenia Gravis After Introduction of Oral Risperidone in a Schizophrenic Saudi Male: A Case Report.

Authors:  Lamees Abualkhair; Ahmad Almaghrabi; Nada Al Edrees; Ahmed Hassab Errasoul
Journal:  Cureus       Date:  2021-12-20

5.  Myasthenia Gravis Masquerading as Status Asthmaticus.

Authors:  Neha Pirwani; Shayna Wrublik; Shashikanth Ambati
Journal:  Case Rep Pediatr       Date:  2021-12-28

Review 6.  Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.

Authors:  Cleonisio Leite Rodrigues; Hermany Capistrano de Freitas; Paulo Reges Oliveira Lima; Pedro Helder de Oliveira Junior; José Marcelino Aragão Fernandes; José Artur Costa D'Almeida; Paulo Ribeiro Nóbrega
Journal:  Neurol Sci       Date:  2022-01-18       Impact factor: 3.830

7.  Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan.

Authors:  Chun-Kai Chang; Wu-Chien Chien; Wan-Fu Hsu; Hao-Yu Chiao; Chi-Hsiang Chung; Yuan-Sheng Tzeng; Shao-Wei Huang; Kuang-Ling Ou; Chih-Chien Wang; Shyi-Jou Chen; Der-Shiun Wang
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

8.  Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis.

Authors:  Yiming Zheng; Xiaoqiu Yuan; Caifeng Zhang; Ran Liu; Haiqiang Jin; Hongjun Hao; Fan Li; Yawen Zhao; Yun Yuan; Zhaoxia Wang; Feng Gao
Journal:  Front Neurol       Date:  2022-03-30       Impact factor: 4.003

9.  Myasthenia Gravis and COVID-19 - A Clinical Checkmate.

Authors:  Vijayalakshmi Sivapurapu; Pratheeba Natarajan; Ravindra Raghuveera Bhat; R Remadevi
Journal:  Anesth Essays Res       Date:  2022-03-08

Review 10.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.